Abstract
Systemic inflammation is implicated in various diseases, yet its upstream determinants remain poorly examined. We conducted a large scale two-sample Mendelian randomisation (MR) study to systematically evaluate the potential causal effects of 3,213 molecular (metabolomic, proteomic), physiological and disease traits on circulating interleukin-6 (IL-6) and C-reactive protein (CRP) levels. Genetic instruments were derived from genome wide association studies and analysed using inverse variance weighted (IVW), weighted median, and MR-Egger methods with multiple testing correction. Bidirectional MR was performed to assess reverse causation.
After Bonferroni correction, evidence of potential causal effects was observed for 72 traits on CRP and 9 traits on IL-6. CRP was predominantly influenced by metabolomic traits, especially lipid and fatty acid measures. Genetically proxied adiposity (body mass index and obesity), triglyceride rich lipoproteins, glycoprotein acetyls (GlycA), and apolipoprotein E increased CRP levels, whereas HDL-related cholesterols, polyunsaturated fatty acids, and glutamine decreased CRP. Most associations were consistent across MR methods, supporting the robustness of these results. As expected, IL-6 had a large effect on CRP.
IL-6 was influenced by primarily adiposity and HDL-related lipid measures, with generally smaller effect sizes and limited support across sensitivity analyses. Bidirectional analyses indicated little evidence that CRP directly drives metabolic traits when restricting to cis-acting instruments, whereas genetically proxied IL-6 signalling showed consistent downstream effects on HDL particle concentration and composition.
Adiposity is a shared upstream determinant of both inflammatory biomarkers, with stronger and broader effects on CRP. These findings suggest that CRP acts as an integrated downstream readout of systemic inflammatory burden, whereas IL-6 reflects a more tightly regulated and context-dependent process. Our work clarifies traits that may causally influence systemic inflammation and highlights biological pathways linking inflammation to cardiometabolic and inflammatory diseases. By mapping upstream determinants of IL-6 and CRP, we also provide a resource to prioritise key drivers for mechanistic study and therapeutic targeting.
Author summary Inflammation plays a vital role in protecting the body from infection and injury but can also become chronic and consequently detrimental. Systemic inflammation is linked to many common diseases, including heart disease, diabetes, and depression. C-reactive protein and Interleukin-6 are widely used markers of inflammation which can be measured in the blood. Although these markers are often elevated in disease, it is not always clear whether they are a cause, a consequence, or a consequence of other underlying processes.
In this study, we used genetic evidence from large population studies to help clarify which traits may have causal influence on levels of these inflammatory markers. By analysing thousands of potential relationships across metabolic, immune, cardiovascular, and mental health traits, we identified several metabolic processes, and related traits such as BMI and Type 2 diabetes, as key drivers of both markers of inflammation. We also found that C-reactive protein appears to reflect a broader range of biological influences than Interleukin-6.
Our findings help to clarify which factors are most likely to sit upstream of systemic inflammation. This improved understanding may help guide future research aimed at preventing or reducing inflammation-related disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GMK acknowledges funding from the UK Medical Research Council (MRC), grant number: MC_UU_00032/6, which forms part of the MRC Integrative Epidemiology Unit at the University of Bristol. This grant supports FRS and CS. TRG, ES, ECMS. GDS acknowledges funding from the UK Medical Research Council (MRC) (grant numbers: MC_UU_00032/1, and MC_UU_00032/3). ECMS is also supported by MRC grant UKRI077. FH acknowledges funding from NIHR Clinical Lectureship programme (no grant code). CD is funded by a postdoctoral fellowship from the South-Eastern Norway Regional Health Authority (2024078). GMK also acknowledges funding from the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical Research Council (grant numbers: MR/W014416/1; MR/S037675/1; MR/Z50354X/1; and MR/Z503745/1). GMK, TRG, HJJ and GDS acknowledge funding from the UK National Institute of Health and Care Research (NIHR) Bristol Biomedical Research Centre (grant number: NIHR 203315). HJJ also acknowledges funding support from Wellcome (grant reference 309183/Z/24/Z).The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available GWAS summary statistics: the download links for which can be found int Supplementary Table 2.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of interest:
TGR is an employee of GlaxoSmithKline. GMK has received royalties from the Cambridge University Press for the Textbook of Immunopsychiatry, and consultancy fees from the Neuroimmune Foundation and the Danish Research Fund (DFF).
No other conflicts of interest.
Funding:
GMK acknowledges funding from the UK Medical Research Council (MRC), grant number: MC_UU_00032/6, which forms part of the MRC Integrative Epidemiology Unit at the University of Bristol. This grant supports FRS and CS. TRG, ES, ECMS. GDS acknowledges funding from the UK Medical Research Council (MRC) (grant numbers: MC_UU_00032/1, and MC_UU_00032/3). ECMS is also supported by MRC grant UKRI077. FH acknowledges funding from NIHR Clinical Lectureship programme (no grant code). CD is funded by a postdoctoral fellowship from the South-Eastern Norway Regional Health Authority (2024078). GMK also acknowledges funding from the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical Research Council (grant numbers: MR/W014416/1; MR/S037675/1; MR/Z50354X/1; and MR/Z503745/1). GMK, TRG, HJJ and GDS acknowledge funding from the UK National Institute of Health and Care Research (NIHR) Bristol Biomedical Research Centre (grant number: NIHR 203315). HJJ also acknowledges funding support from Wellcome (grant reference 309183/Z/24/Z).The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.
Data Availability
All data produced in the present work are contained in the manuscript.
